Understanding how Medicaid's approval process affects access to quitting smoking medications
Examining the Impact of Medicaid's Prior Authorization Requirements for Tobacco Cessation Medications on Tobacco Cessation Medication Prescriptions
['FUNDING_R03'] · VANDERBILT UNIVERSITY · NIH-10758252
This study looks at how the rules for getting tobacco quitting medications through Medicaid affect low-income smokers in Colorado, to see if making it easier to access these treatments can help more people quit smoking.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY (nih funded) |
| Locations | 1 site (Nashville, UNITED STATES) |
| Trial ID | NIH-10758252 on ClinicalTrials.gov |
What this research studies
This research investigates how Medicaid's prior authorization requirements for tobacco cessation medications impact the ability of low-income smokers to access these vital treatments. By analyzing health care claims data from Colorado's Medicaid program, the study aims to determine whether these requirements hinder or help the prescribing of cessation medications. The goal is to provide insights into whether removing such barriers can improve access to smoking cessation resources for those who need them most.
Who could benefit from this research
Good fit: Ideal candidates for this research are low-income smokers enrolled in Medicaid who are seeking assistance with quitting smoking.
Not a fit: Patients who are not enrolled in Medicaid or who do not smoke may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved access to tobacco cessation medications for low-income individuals, potentially increasing smoking cessation rates.
How similar studies have performed: Previous research has indicated that reducing barriers to medication access can significantly improve treatment outcomes, suggesting that this approach may yield beneficial results.
Where this research is happening
Nashville, UNITED STATES
- VANDERBILT UNIVERSITY — Nashville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DILLENDER, MARCUS OWEN — VANDERBILT UNIVERSITY
- Study coordinator: DILLENDER, MARCUS OWEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.